Butcompanies for a whilehave beenseekingways to rewardexecutives'long-term performance andlimitexcessiverisk-taking, according tocompensationconsultants.
The companieshavebeen criticized for taking three years since Zetia was approved to start this key study, called IMPROVE-IT, to demonstrate that Zetia adds further benefit to Zocor, which has already been shown to prevent heart attacks.